Press Releases

Regarding full details of the resolutions, referral is made to the notice convening the general meeting and the complete proposals. The notice convening the general meeting and the complete proposals are available at the company’s website, http://www.sedanamedical.com...

First quarter 2024 CEO comments Off to a strong start with record sales in Q1 Coming out of a successful 2023, we have established ambitious goals for 2024: achieving an all-time-high in sales, attaining EBITDA break-even outside of the US within the...

“The completion of the INSPiRE-ICU 1 study marks a true milestone for Sedana Medical. Launching the randomized controlled multicenter studies across the large and diverse US healthcare landscape, in mixed surgical and medical ICUs with a different...

NOTICE OF ANNUAL GENERAL MEETING IN SEDANA MEDICAL AB (PUBL) The annual general meeting of Sedana Medical AB (publ) will be held on Wednesday, 22 May 2024 at 2:00 pm at Vendevägen 89, Danderyd. Registration begins at 1:30 pm. RIGHT TO ATTEND AND...

“During the year 2023, Sedana Medical took several important steps towards becoming a stronger and healthier company. We have returned to consistent sales growth after the challenging post-Covid period, we have taken decisive steps towards reaching...

According to the financial calendar, Sedana Medical plans to publish the interim report for the first quarter 2024 on Thursday April 25 at approximately 07.00 CET. Sedana Medical hereby invites to a presentation of the report on the same day, where the...

Fourth quarter 2023 January-December 2023 CEO comments Full year sales at upper end of financial guidance and an exciting year ahead Reflecting on the progress we have made during the year 2023, I am pleased to see that Sedana Medical stands as a much...

According to the financial calendar, Sedana Medical plans to publish the fourth quarter and year-end report for 2023 on Thursday February 15 at approximately 07.00 CET. Sedana Medical hereby invites to a presentation of the report on the same day, where...

The submission is based on the results of the IsoCOMFORT trial, a randomised active-controlled assessor-blinded study comparing the efficacy and safety of sedation with inhaled isoflurane, administered via the company’s medical device Sedaconda...

In 2021, Sedana Medical’s proprietary pharmaceutical Sedaconda (isoflurane) received its first market authorization in Europe for administration via the medical device Sedaconda ACD for inhaled sedation of mechanically ventilated patients in intensive...